3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
96
Rectal Neoplasms
42
Colonic Neoplasms
38
Stomach Neoplasms
31
Pancreatic Neoplasms
31
Neoplasm Metastasis
24
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Neoplasms
21
Esophageal Neoplasms
19
Burkitt Lymphoma
15
Adenocarcinoma Of Esophagus
14
Lymphoma
13
Leukemia
8
Adenocarcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Osteosarcoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Mantle-Cell
4
Leukemia, Biphenotypic, Acute
4
Gastrointestinal Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Hepatocellular
4
Liver Neoplasms
3
Intestinal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Bile Duct Neoplasms
3
Somatostatinoma
2
Interventions
pembrolizumab
3
Nivolumab
2
vicriviroc
1
spartalizumab
1
relatlimab
1
copanlisib
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Spinocerebellar Degenerations
×
Leucovorin
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts